welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Leanne Ward, MD, FRCPC

Medical Director
Pediatric Bone Health and Rare Bone Disease Program
Division of Endocrinology and Metabolism
CHEO Research Institute
401 Smyth Road
Ottawa, Ontario, United States

Dr. Leanne Ward is a professor of pediatrics at the University of Ottawa where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Medical Director of the Pediatric Bone Health and Rare Bone Disease Clinical and Research Programs at the Children’s Hospital of Eastern Ontario, and a pediatric endocrinologist in the Division of Endocrinology and Metabolism.

Dr. Ward leads local, national and global research initiatives in the study of mechanisms, epidemiology and treatment of bone disorders in children, with an emphasis on osteoporosis in children with serious chronic illnesses. Dr. Ward’s research program is dedicated to the study of bone development and the diagnosis and treatment of bone disorders in children. She has been the principal investigator of the “STOPP” research program (STeroid-induced Osteoporosis in the Pediatric Population), a pan-Canadian project funded by the Canadian Institutes of Health Research to evaluate the effect of glucocorticoids on bone health in children with chronic illnesses.

Dr. Ward actively leads and collaborates on a number of clinical trials for children with osteogenesis imperfecta, rickets and chronic illness osteoporosis. She has served as an endocrinology and bone health advisor to various international organizations on skeletal health in children, including the Centres for Disease Control Clinical Care Guidelines for Duchenne Muscular Dystrophy, the International Late Effects of Childhood Cancer Guideline Harmonization Group and the International Conference on Children’s Bone Health.


Representative Publications: 

Bone Health and Osteoporosis Management of the Patient with Duchenne Muscular Dystrophy

Obesity and Endocrine Management of the Patient With Duchenne Muscular Dystrophy

Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy

Phase IIa Trial in Duchenne Muscular Dystrophy Shows Vamorolone is a First-In-Class Dissociative Steroidal Anti-Inflammatory Drug 

Diagnosis and Management of Duchenne Muscular Dystrophy, Part 1: Diagnosis, and Neuromuscular, Rehabilitation, Endocrine, and Gastrointestinal and Nutritional Management